Jiangsu Jibeier Pharmaceutical (688566) Q2 2024 earnings summary

Executive summary

• Achieved revenue of ¥433.66 million for H1 2024, up 3.55% year-over-year; net profit attributable to shareholders rose 26.74% to ¥122.01 million.

• R&D investment increased to 8.15% of revenue, with major projects advancing in clinical trials.

• Expanded product pipeline in oncology, depression, and diabetes, with multiple innovative drugs in clinical and preclinical stages.

• Strengthened marketing and sales network, with core products maintaining leading market positions.

Financial highlights

• Revenue: ¥433.66 million, up 3.55% year-over-year.

• Net profit attributable to shareholders: ¥122.01 million, up 26.74% year-over-year.

• Operating cash flow: ¥131.19 million, up 19.76% year-over-year.

• Basic and diluted EPS: ¥0.65, up 27.45% year-over-year.

• R&D expenses: ¥35.34 million, with 50.78% capitalized due to clinical progress.

Outlook and guidance

• Continued focus on innovative drug R&D, with key projects (JJH201501, JJH201601) progressing in clinical trials.

• Ongoing expansion of production and R&D facilities, including new high-end formulation center.

• Anticipates further revenue and profit growth as new products advance toward commercialization.